HK Stock Market Move | HENLIUS (02696) rose nearly 12% in early trading. Hanszhuang has been officially recommended by the UK NICE and included in the NHS reimbursement system.

HENLIUS (02696) rose nearly 12% in early trading, and as of press time, it was up 7.07% to HK$68.95 with a trading volume of HK$52.73 million. On the news front, according to HENLIUS' official Weibo account, Accord Healthcare UK (hereinafter referred to as "Accord") and the company recently announced that the drug Hanslui (Sulruilumab, European trade name: Hetronifly) has been recommended by the National Institute for Health and Clinical Excellence (NICE) in the UK for formal inclusion in the routine clinical use range of the National Health Service (NHS) in England and Wales. With the formal recommendation from NICE and completion of listing on NHS, Hanslui becomes the first anti-PD-1 monoclonal antibody approved by NICE for use in ES-SCLC treatment in England and Wales. Sulruilumab is an immunotherapy drug that works by helping the body's immune system identify and attack cancer cells. The drug has previously been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK, becoming the first anti-PD-1 monoclonal antibody approved for ES-SCLC treatment in the UK.